The position of cyproterone acetate (CPA), a steroidal anti‐androgen, in the treatment of prostate cancer

  title={The position of cyproterone acetate (CPA), a steroidal anti‐androgen, in the treatment of prostate cancer},
  author={Herman J. de Voogt},
  journal={The Prostate},
Cyproterone acetate is a steroidal anti‐androgen that blocks the androgen‐receptor interaction and reduces serum testosterone through its weak anti‐gonadotropic action. It can be regarded as the only anti‐hormone that causes complete androgen blockade as monotherapy. Many animal experiments and several clinical phase II and phase III trials have demonstrated that it deserves a place in the endocrine therapy of advanced prostate cancer, particularly for those patients who find orchidectomy… Expand
The future of antihormone therapy: innovations based on an established principle
Preclinical experiments indicate that combination therapy as well as the extension of endocrine treatments to several other tumor entities are promising approaches for further developments. Expand
Cyproterone acetate acts as a disruptor of the aryl hydrocarbon receptor
This study helps to understand why CPA induces acute hepatitis, gene mutation, and many other side effects, and may trigger further studies investigating the relationships between CPA, glucocorticoid receptor and castration-resistant prostate cancer in the future. Expand
Androgen deprivation therapy for prostate cancer
This review discusses the first-line androgen deprivation methods and regimens presently in use with special attention paid to their side effects and the management of them, as well as the question of when to initiate androgens deprivation therapy. Expand
This chapter systematically review clinical and experimental evidence supporting current strategies of hormonal therapy in PCa, the second leading cause of cancer-related death among men in the United States. Expand
Hormonal Therapy in Metastatic Prostate Cancer: Current Perspectives and Controversies
This review assesses the present status of hormonal therapy in metastatic prostate cancer and specifically deals with those aspects of androgen ablation therapy that are still a subject of debate. Expand
Cyproterone acetate monotherapy in advanced prostatic carcinoma
Cyproterone acetate was given as monotherapy to 18 patients with advanced prostatic carcinoma at a weekly dose of 300 mg, showing favourable results, as compared with other forms of therapy in advanced prostatics carcinoma. Expand
Effect of Small Molecules Modulating Androgen Receptor (SARMs) in Human Prostate Cancer Models
In vitro results highlight the antitumor activity of the two novel molecules (R)-9 and (S)-11, making them a potentially attractive option for the treatment of CRPC. Expand
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
There is an urgent need for the development of novel targeted and immune therapies for this subtype of prostate cancer, when more deadly small-cell prostate cancers are induced by thorough androgen deprivation and androgen receptor ablation. Expand
The Current State of Hormonal Therapy for Prostate Cancer
Androgen deprivation therapy remains a mainstay of treatment for men with prostate cancer. New uses for hormonal therapy, including use in the adjuvant and neoadjuvant setting, are being evaluated.Expand
Recent advances in the investigation of curcuminoids
The literature between 1976 and mid-2008 on the anti-inflammatory, anti-oxidant,Anti-HIV, chemopreventive and anti-prostate cancer effects of curcuminoids are reviewed. Expand